Human recombinant interferon alpha-2a plus 3'-azido-3'-deoxythymidine. Synergistic growth inhibition with evidence of impaired DNA repair in human colon adenocarcinoma cells

Biochemical Pharmacology

Volumn 53, Issue 4, 1997, Pages 571-580

  Darnowski, James W ^a   Davol, Pamela A ^b   Goulette, Frederick A ^a  

^a BROWN UNIVERSITY   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

AZT; DNA excision repair; DNA polymerase beta; human recombinant interferon alpha 2a; p53 protein; thymidine kinase

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE BETA; RECOMBINANT ALPHA2A INTERFERON; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; ZIDOVUDINE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; DNA FRAGMENTATION; DNA REPAIR; DNA-DIRECTED DNA POLYMERASE; HUMANS; INTERFERON ALFA-2A; THYMIDINE KINASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; ZIDOVUDINE;

EID: 0031581872     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00824-6     Document Type: Article

References (56)

1. 1. Fischl MA, Richmann DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, Jackson GG, Durack DT, King D and the AZT Collaborative Working Group, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317: 185-191, 1987.
2. 2. Mitsuya H, Weinhold KJ, Furman PA, St. Clair MH, Nusinoff-Lehrman S, Gallo RC, Bolognesi D, Barry DW and Broder S, 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82: 7096-7100, 1985.
3. 3. Brunetti I, Falcone A, Calabresi P, Goulette FA and Darnowski JW, 5-Fluorouracil enhances azidothymidine cytotoxicity: In vitro, in vivo and biochemical studies. Cancer Res 50: 4026-4031, 1990.
4. 4. Darnowski JW and Goulette FA, Increased azidothymidine metabolism in the presence of fluorouracil reflects increased thymidine kinase activity. Proc Am Assoc Cancer Res 34: 302, 1993.
5. 5. Tosi P, Calabresi P, Goulette FA, Renaud CA and Darnowski JW, Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. Cancer Res 52: 4069-4073, 1992.
6. 6. Pressacco J and Erlichman C, Combination studies with 3′-azido-3′-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem Pharmacol 46: 1989-1997, 1993.
7. 7. Posner MR, Darnowski JW, Calabresi P, Brunetti I, Corvese D, Curt G, Cummings FJ, Clark J, Browne M, Beitz J and Weitberg AB, Oral zidovudine, continuous-infusion fluorouracil, and oral leucovorin calcium: A phase I study. J Natl Cancer Inst 82: 1710-1714, 1990.
8. 8. Posner MR, Darnowski JW, Weitberg AB, Dudley MN, Corvese D, Cummings FJ, Clark J, Murray C, Clendennin N, Bigley J and Calabresi P, High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A Phase I trial. Cancer 70: 2929-2934, 1992.
9. 9. Beitz JG, Darnowski JW, Cummings FJ, Browne MJ, Clark JW, Bigley JW and Weitberg AB, Phase I trial of high-dose infused zidovudine combined with leucovorin and fluorouracil. Cancer Invest 13: 464-469, 1995.
10. 10. Posner M, Darnowski J, Tessitore J, Bigley J, Parker L, Stuart K and Huberman N, A Phase I trial of high dose, intravenous zidovudine (AZT) and 5-fluorouracil/leucovorin (FUra/L). Proc Am Soc Clin Oncol 12: 162, 1993.
11. 11. Browne MJ, Beitz J, Clark JW, Cummings FJ, Weitberg A, Murray C and Darnowski JW, A Phase I study of zidovudine (AZT) combined with methotrexate in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 12: 163, 1993.
12. 12. Clark JW, Beitz J, Cummings F, Sikov W, Browne M, Akerley W, Wanebo H, Weitberg AB, Kennedy T, Bigley J and Darnowski JW, Phase II study of 5-fluorouracil (5-FU), leucovorin (LV) and azidothymidine (AZT) in patients with metastatic colon cancer. Proc Am Soc Clin Oncol 14: 220, 1995.
13. 13. Goldstein D and Laszlo J, Interferon therapy in cancer: From imaginon to interferon. Cancer Res 46: 4315-4329, 1986.
14. 14. Trotta PP, Preclinical biology of alpha interferons. Semin Oncol 13: 3-12, 1986.
15. 15. Lengyel P, Biochemistry of interferons and their actions. Annu Rev Biochem 51: 251-282, 1982.
16. 16. Yan C and Tamm I, Identification of a new interferon-α/β inducible DNA-binding protein that interacts with the regulatory element of 2′,5′-oligoadenylate synthetase ME-12 gene. J Interferon Res 12: 425-430, 1992.
17. 17. Clark JW and Longo DL, Interferons in cancer therapy. Cancer Updates 1: 1-15, 1987.
18. 18. Levy D, Larner A, Chaudhuri A, Babiss LE and Darnell JE Jr, Interferon-stimulated transcription: Isolation of an inducible gene and identification of its regulatory region. Proc Natl Acad Sci USA 83: 8929-8933, 1986.
19. 19. Rutherford MM, Hannigan GE and Williams BRG, Interferon-induced binding of nuclear factors to promote elements of the 2-5A synthetase gene. EMBO J 7: 751-759, 1988.
20. 20. Friedman RL, Manly SP, McMahon M, Kerr IM and Stark GR, Transcriptional and post-transcriptional regulation of interferon-induced gene expression in human cells. Cell 38: 745-755, 1984.
21. 21. Catalda A, Santavenere E, Vitale M, Trubiani O, Lisio R, Tulipano G, Domenicantonio LD, Zamai L and Miscia S, Interferon affects cell growth progression by modulating DNA polymerase activity. Cell Prolif 25: 225-231, 1992.
22. 22. Tanaka M, Kimura K and Yoshida S, Inhibition of mammalian DNA polymerases by recombinant α-interferon and γ-interferon. Cancer Res 47: 5971-5974, 1987.
23. 23. Bergerat J-P, Herbrecht R, Dufour P, Jacqmin D, Bollack C, Prevot G, Bailly G, de Garis S, Juraschek F and Oberling F, Combination of recombinant interferon alpha-2a and vinblastine in advanced renal cell cancer. Cancer 62: 2320-2324, 1988.
24. 24. Muss HB, Welainder C, Capanera M, Reavis K, Cruz JM, Cooper MR, Jackson DV Jr, Richards F II, Stuart JJ, Spurr CL, White DR, Zekan PJ and Capizzi RL, Interferon and doxorubicin in renal cell carcinoma. Cancer Treat Rep 69: 721-722, 1985.
25. 25. Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, Derby S, Murray P and Houston C, Interferon α2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 66: 2470-2475, 1990.
26. 26. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shephard B, DuBrow R, Campos L, Quaraishi M, Faintuck J, Abbruzzese JL, Gutterman J and Levin B, Phase II study of fluorouracil and recombinant interferon α2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027-2031, 1990.
27. 27. Schwartz EL, Hoffman M, O'Connor CJ and Wadler S, Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 182: 1232-1239, 1992.
28. 28. Gewert DR, Shah S and Clemens MJ, Inhibition of cell division by interferons. Changes in the transport and intracellular metabolism of thymidine in human lymphoblastoid (Daudi) cells. Eur J Biochem 116: 487-492, 1981.
29. 29. Houghton JA, Morton CL, Adkins DA and Rahman A, Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-α2a in colon carcinoma cells. Cancer Res 53: 4243-4250, 1993.
30. 30. Darnowski JW and Goulette FA, Synergistic cytotoxicity with alpha interferon and azidothymidine in HCT-8 cells reflects increased azidothymidine incorporation into DNA. Proc Am Assoc Cancer Res 35: 334, 1994.
31. 31. Darnowski JW, Hankinson G and Goulette F, Alpha-interferon induced inhibition of DNA repair increases the cytotoxicity of azidothymidine in HCT-8 cells. Proc Am Assoc Cancer Res 36: 298, 1995.
32. 32. Tompkins WAF, Watrach AM, Schmale JD, Schultz RM and Harris JA, Cultural and antigenic properties of newly established cell strains derived from adenocarcinoma of the human colon and rectum. J Natl Cancer Inst 52: 1101-1110, 1974.
33. 33. Darnowski JW and Goulette FA, 3′-Azido-3′-deoxythymidme cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem Pharmacol 48: 1797-1805, 1994.
34. 34. Kalman TI and Yalowich JL, Studies of the effects of folic acid antagonists on thymidylate synthetase activity in intact mammalian cells. Dev Biochem 4: 671-676, 1979.
35. 35. Darnowski JW and Handschumacher RE, Tissue uridine pools: Evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res 46: 3490-3494, 1986.
36. 36. Sharma M, Jain R, Ionescu E and Darnowski JW, Quantitacive analysis of 3′-azido-3′-deoxythymidine incorporation into DNA in human colon tumor cells. Bioconjug Chem 6: 536-540, 1995.
37. 37. Hengstler JG, Fuchs J and Oesch F, DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res 52: 5622-5626, 1992.
38. 38. Davol PA, Goulette FA, Frackelton AR Jr and Darnowski JW, Modulation of p53 expression by human recombinant interferon α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res 56: 2522-2526, 1996.
39. 39. Elion GB, Singer S and Hitchings GH, Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208: 477-488, 1954.
40. 40. Chou TC and Talalay P, Quantitative analysis of dose-effect relationships: The combined effect of multiple drugs and enzyme inhibitors. In: Advances in Enzyme Regulation (Ed. Weber G), pp. 27-55. Pergamon Press, New York, 1984.
41. 41. Chu E, Zinn S, Boarman D and Allegra CJ, Interaction of γ-interferon and fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50: 5834-5840, 1990.
42. 42. Furman PA, Fyfe JA, St. Clair MH, Weinhold K, Rideout JL, Freeman GA, Nusinoff Lehrman S, Bolognesi DP, Broder S, Mitsuya H and Barry DW, Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 83: 8333-8337, 1986.
43. 43. Waga S and Stillman B, Anatomy of a DNA replication fork revealed by reconstitution of SV40 DNA replication in vitro. Nature 369: 207-212, 1994.
44. 44. Sancar A, Mechanisms of DNA excision repair. Science 266: 1954-1965, 1994.
45. 45. Miller MR and Chinault DN, The roles of DNA polymerases α, β and γ in DNA repair synthesis induced in hamster and human cells by different DNA damaging agents. J Biol Chem 257: 10204-10209, 1982.
46. 46. Price BD and Park SJ, DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 54: 896-899, 1994.
47. 47. Marx J, New link found between p53 and DNA repair. Science 266: 1321-1322, 1994.
48. 48. Milne DM, Campbell LE, Campbell DG and Meek DW, p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase JNK1. J Biol Chem 270: 5511-5518, 1995.
49. 1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
50. 50. Elias E and Sandoval JM, Interferon effects upon fluorouracil metabolism in HL60 cells. Biochem Biophys Res Commun 163: 867-874, 1989.
51. 51. Vazquez-Padua MA, Starnes MC and Cheng Y-C, Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun 2: 55-62, 1990.
52. 52. Harrington JA, Reardon JE and Spector T, 3′-Azido-3′-deoxythymidine (AZT) monophosphate: An inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother 37: 918-920, 1993.
53. 53. Fornace AJ Jr, Zmudzka B, Hollander MC and Wilson SH, Induction of β-polymerase mRNA by DNA-damaging agents in Chinese hamster ovary cells. Mol Cell Biol 9: 851-853, 1989.
54. 54. Horton JK, Srivastava DK and Wilson SH, Down-regulation of DNA polymerase beta (beta-pol) sensitizes mammalian cells to specific DNA damaging agents. Proc Am Assoc Cancer Res 35: 394, 1994.
55. 55. Narayan S, Beard WA and Wilson SH, DNA damage-induced transcriptional activation of a human DNA polymerase beta chimeric promoter: Recruitment of preinitiation complex in vitro by ATF/CREB. Biochemistry 34: 73-80, 1995.
56. 56. Smith ML, Chen IT, Zhan Q, O'Connor PM and Fornace AJ Jr, Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogens 10: 1053-1059, 1995.